stiderm gel 15 mg/15 mg/ 50 mg
bilim pharmaceuticals a.Ș. - mepyraminum maleas + lidocainum hydrochloridum + colecalciferol. resin. - gel - 15 mg/15 mg/ 50 mg
lidocain 10% spray cutanat, soluţie
egis pharmaceuticals plc - lidocaini hydrochloridum - spray cutanat, soluţie - 10%
stiderm gel 15 mg/15 mg/50 mg
bilim ilac sanayi ve ticaret a.Ș. - mepyraminum maleas + lidocainum hydrochloridum + colecalciferol. resin. - gel - 15 mg/15 mg/50 mg
lidocain 4,6 mg/doză spray cutanat, soluţie
egis pharmaceuticals plc - lidocaini hydrochloridum - spray cutanat, soluţie - 4,6 mg/doză
lidocain spray cutanat, solutie 10%
egis pharmaceuticals plc - spray cutanat, solutie - 10%
lidiam 40 mg/g
qp-services uk ltd. - marea britanie - lidocainum - crema - 40mg/g - antipruriginoase, incl. antihistaminice, anestezice antipruriginoase, incl. antihistaminice, anestezice
lidiaq 40 mg/g
adamed pharma s.a. - polonia - lidocainum - crema - 40mg/g - antipruriginoase, incl. antihistaminice, anestezice antipruriginoase, incl. antihistaminice, anestezice
lidocain 100 mg/ml spray cutanat, soluţie
sc flumed-farm srl - lidocaini hydrochloridum - spray cutanat, soluţie - 100 mg/ml
dabigatran etexilate accord
accord healthcare s.l.u. - dabigatran etexilat sub formă de mesilat - venous thromboembolism; arthroplasty, replacement - agenți antitrombotici - prevention of venous thromboembolic events.
tafinlar
novartis europharm limited - dabrafenib mesilate - melanomul - agenți antineoplazici - melanomadabrafenib as monotherapy or in combination with trametinib is indicated for the treatment of adult patients with unresectable or metastatic melanoma with a braf v600 mutation (see sections 4. 4 și 5. tratamentul adjuvant al melanomadabrafenib în combinație cu trametinib este indicat pentru tratamentul adjuvant al pacienților adulți cu etapa a iii-a melanom cu mutație braf v600, în urma rezecției complete. non-small cell lung cancer (nsclc)dabrafenib in combination with trametinib is indicated for the treatment of adult patients with advanced non-small cell lung cancer with a braf v600 mutation.